GLEAMER Receives FDA Clearance for Its Artificial Intelligence Software to Help Detect and Localize Fractures


GLEAMER, a French medtech company pioneering the use of artificial intelligence technology in the practice of radiology, announced today that the United States Food and Drug Administration has cleared its BoneView® AI software for use by U.S. healthcare specialists to aid in diagnosing fractures and traumatic injuries on X-rays. In a U.S. study recently published by Boston University School of Medicine, BoneView was shown to help detect and localize fractures over the entire appendicular skeleton, rib cage, thoracic and lumbar spine, improving sensitivity and specificity, while reducing reading time.

Read More

Next Post

Prescient Healthcare Group Acquires Strategic North

Prescient, a biopharma product and portfolio strategy firm, announces the recent acquisition of Strategic North, a global commercial strategy consultancy that partners with a wide range of pharmaceutical companies to help them better understand how their customers make decisions in order to unlock the full potential of their brands. Read […]